SNAI2 and melanoma: Indeed, the loss of SNAI2/ZEB2 combined with the gain of ZEB1 is a factor involved in the poor prognosis of melanoma patients [16] and is associated with resistance to MAPK-targeting [17] and immune [18] therapies.